Dataset Information


ScRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.

ABSTRACT: Targeting oncogenic pathways holds promise for brain tumor treatment, but inhibition of Sonic Hedgehog (SHH) signaling has failed in SHH-driven medulloblastoma. Cellular diversity within tumors and reduced lineage commitment can undermine targeted therapy by increasing the probability of treatment-resistant populations. Using single-cell RNA-seq and lineage tracing, we analyzed cellular diversity in medulloblastomas in transgenic, medulloblastoma-prone mice, and responses to the SHH-pathway inhibitor vismodegib. In untreated tumors, we find expected stromal cells and tumor-derived cells showing either a spectrum of neural progenitor-differentiation states or glial and stem cell markers. Vismodegib reduces the proliferative population and increases differentiation. However, specific cell types in vismodegib-treated tumors remain proliferative, showing either persistent SHH-pathway activation or stem cell characteristics. Our data show that even in tumors with a single pathway-activating mutation, diverse mechanisms drive tumor growth. This diversity confers early resistance to targeted inhibitor therapy, demonstrating the need to target multiple pathways simultaneously.


PROVIDER: S-EPMC6925218 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5079386 | BioStudies
2019-04-13 | GSE129730 | GEO
2008-01-01 | S-EPMC2538687 | BioStudies
2017-01-01 | S-EPMC5680121 | BioStudies
2020-01-01 | S-EPMC7443968 | BioStudies
2019-01-01 | S-EPMC7142219 | BioStudies
2007-01-01 | S-EPMC1815291 | BioStudies
2017-01-01 | S-EPMC5512702 | BioStudies
2019-01-01 | S-EPMC6367140 | BioStudies
2012-01-01 | S-EPMC3338642 | BioStudies